Therapeutic Areas

Latest News

Credit: freshidea | stock.adobe.com
Muvalaplin Found to Significantly Lower Lipoprotein(a) Levels, Offering Hope for Cardiovascular Disease Patients

November 21st 2024

The Phase II KRAKEN trial demonstrated that muvalaplin, Eli Lilly's first-in-class oral small molecule inhibitor, significantly reduces lipoprotein(a) levels with minimal adverse effects, offering a promising new approach to addressing a major cardiovascular risk factor.

Credit: Lightgeo | stock.adobe.com
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing

November 20th 2024

Credit: Rasi | stock.adobe.com
Colchicine Fails to Reduce Cardiovascular Events After Myocardial Infarction, Increases Diarrhea Risk

November 19th 2024

Credit: blacksalmon | stock.adobe.com
Tirzepatide Reduces Heart Failure Risk, Improves Physical Function in HFpEF Patients

November 18th 2024

Bimzelx. Image Credit: UCB
Two-Year Phase III Data Confirm Long-Term Efficacy, Safety of Bimzelx in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, Ankylosing Spondylitis

November 15th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.